Copy to clipboard 
New product introductions and a dedicated orthopedics sales channel have Integra LifeSciences positioned for mid-single digit growth in the second half of 2019.
- Orthopedic sales impacted by case scheduling delays in high volume accounts.
- While still negative, sales of lower extremity fixation products increased sequentially to help stabilize that business, driven largely by the Panta 2 Nail.
- Growth in joint replacement driven by ankle and shoulder products.
- Company leadership expects mid-single-digit growth in orthopedics in the second half of the year, due to the newly established dedicated sales channel.
- To achieve growth acceleration in the second half, the company has increased manufacturing capacity and resources allotted to entering new markets.
Segment sales and growth on an as-reported basis are as follows ($MM).
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement Extremities | $9.1 | $9.0 | $0.1 | 1.3% |
| Trauma | $12.6 | $13.0 | -$0.4 | -2.8% |
| Total | $21.8 | $22.0 | -$0.3 | -1.2% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Joint Replacement Extremities | $18.2 | $18.1 | $0.1 | 0.7% |
| Trauma | $26.2 | $26.6 | -$0.3 | -1.3% |
| Total | $44.4 | $44.7 | -$0.2 | -0.5% |
Sales by geographic region are as follows ($MM).
| Geographic Region | 2Q19 | 2Q18 | $ Chg | % Chg |
| US | $15.3 | $15.2 | $0.1 | 0.6% |
| Ex-US | $6.4 | $6.8 | -$0.4 | -5.2% |
| EMEA | $3.2 | $3.2 | $0.0 | -1.2% |
| Asia Pacific | $2.2 | $2.3 | -$0.1 | -3.6% |
| Rest of World | $1.1 | $1.3 | -$0.2 | -17.6% |
| Total | $21.8 | $22.0 | -$0.3 | -1.2% |
Net earnings, inclusive of all revenue, are as follows ($MM).
| 2Q19 | Amt | % of Sales |
| Sales | $383.6 | |
| Cost of Sales | -$143.7 | 37.4% |
| Selling and Admin | -$165.4 | 43.1% |
| R & D | -$17.6 | 4.6% |
| Other | -$27.2 | 7.1% |
| Net Earnings | $29.7 | 7.8% |
Sources: Integra LifeSciences; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
New product introductions and a dedicated orthopedics sales channel have Integra LifeSciences positioned for mid-single digit growth in the second half of 2019.
Orthopedic sales impacted by case scheduling delays in high volume accounts.
While still negative, sales of lower extremity fixation products increased sequentially...
New product introductions and a dedicated orthopedics sales channel have Integra LifeSciences positioned for mid-single digit growth in the second half of 2019.
- Orthopedic sales impacted by case scheduling delays in high volume accounts.
- While still negative, sales of lower extremity fixation products increased sequentially to help stabilize that business, driven largely by the Panta 2 Nail.
- Growth in joint replacement driven by ankle and shoulder products.
- Company leadership expects mid-single-digit growth in orthopedics in the second half of the year, due to the newly established dedicated sales channel.
- To achieve growth acceleration in the second half, the company has increased manufacturing capacity and resources allotted to entering new markets.
Segment sales and growth on an as-reported basis are as follows ($MM).
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement Extremities | $9.1 | $9.0 | $0.1 | 1.3% |
| Trauma | $12.6 | $13.0 | -$0.4 | -2.8% |
| Total | $21.8 | $22.0 | -$0.3 | -1.2% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Joint Replacement Extremities | $18.2 | $18.1 | $0.1 | 0.7% |
| Trauma | $26.2 | $26.6 | -$0.3 | -1.3% |
| Total | $44.4 | $44.7 | -$0.2 | -0.5% |
Sales by geographic region are as follows ($MM).
| Geographic Region | 2Q19 | 2Q18 | $ Chg | % Chg |
| US | $15.3 | $15.2 | $0.1 | 0.6% |
| Ex-US | $6.4 | $6.8 | -$0.4 | -5.2% |
| EMEA | $3.2 | $3.2 | $0.0 | -1.2% |
| Asia Pacific | $2.2 | $2.3 | -$0.1 | -3.6% |
| Rest of World | $1.1 | $1.3 | -$0.2 | -17.6% |
| Total | $21.8 | $22.0 | -$0.3 | -1.2% |
Net earnings, inclusive of all revenue, are as follows ($MM).
| 2Q19 | Amt | % of Sales |
| Sales | $383.6 | |
| Cost of Sales | -$143.7 | 37.4% |
| Selling and Admin | -$165.4 | 43.1% |
| R & D | -$17.6 | 4.6% |
| Other | -$27.2 | 7.1% |
| Net Earnings | $29.7 | 7.8% |
Sources: Integra LifeSciences; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
